A newly approved treatment for spinal muscular atrophy is moving toward U.S. availability, giving eligible children and adults an additional option to address muscle weakness.
Scholar Rock announced September 11 that the Food and Drug Administration approved Isembyld, also known as apitegromab-mstn. The company said shipments would begin in the coming days as its commercial launch gets underway.
The approval covers patients aged 2 and older who are already receiving a survival motor neuron 2, or SMN2, targeted treatment. The FDA describes Isembyld as the first approved SMA therapy that directly targets muscle loss while working alongside existing treatments.
How The Treatment Works
SMA is a rare genetic disease that causes progressive muscle weakness and wasting. A faulty SMN1 gene leaves the body without enough of a protein needed for motor neuron survival.
Existing SMN2-targeted medicines help the body produce that protein. Patients with more advanced disease can still face substantial movement limitations, according to the FDA.
Isembyld blocks activation of myostatin, a protein involved in regulating muscle growth, according to Scholar Rock.
The Muscular Dystrophy Association welcomed the approval as a milestone for families seeking improvements in motor function and independence.
“This is what progress looks like,” Angela Lek, the association’s chief research officer, said in its September 11 statement.
The organization said the treatment addresses continued motor decline among people already receiving SMA therapies. It also credited sustained research investment with helping bring muscle-directed treatment to patients.
What The Clinical Trial Found
The FDA evaluated a 52-week trial involving 188 participants ages 2 to 21. All were already receiving an approved SMN2-targeted treatment.
Among children ages 2 to 12, those receiving the recommended Isembyld dose showed improved motor function compared with the placebo group. Clinically meaningful improvement occurred in 34.2% of treated patients, compared with 13.5% of placebo recipients, according to the FDA’s trial summary.
Safety findings included an increased risk of fractures, including serious fractures. Common adverse reactions included respiratory infections, vomiting, cough and headache. The FDA also warned of potential fetal harm and effects on reproductive function.
Patient Support As Launch Begins
Scholar Rock said its patient support program is available to help people prescribed Isembyld understand insurance coverage, financial assistance eligibility and infusion arrangements.
The company said eligible patients may receive infusions in hospitals, infusion centers, or at home. Its launch announcement also outlined plans to work with commercial and government insurers on access.
The Muscular Dystrophy Association says its resource center provides information and support for families and medical professionals. The organization has invested more than $50 million in SMA research and supports a nationwide network of care centers.
Provided by Dallas Express
